BioNTech's BNT327 shows promising survival data in lung cancer trial, with 72.7% of patients surviving one year, ...

Novo Nordisk partners with Lexicon Pharmaceuticals for obesity drug LX9851 in deal worth up to $1B, including $75M upfront ...

After a 6-year run, CRISPR Therapeutics COO Julianne Bruno is stepping out the door to pursue other opportunities. Bruno's ...

Merck KGaA pays $85M for global rights to Abbisko's pimicotinib, a CSF-1R inhibitor for TGCT that competes with Daiichi ...

Alumis and Acelyrin had merger talks in 2023 before current deal. SEC filing shows earlier reverse merger attempt, followed ...

HHS announces major downsizing, cutting 20,000 jobs total across FDA, CDC, and NIH. New Administration for Healthy America to ...

After an IPO this year, Metsera is making its best effort to catch up to obesity drug giants Eli Lilly and Novo Nordisk.

HHS’ plans to eliminate almost 20% of the FDA’s staff will likely take a major toll on policy, communications and other ...

President Donald Trump’s threatened tariffs on pharmaceuticals are incentivizing drugmakers to build more manufacturing ...

Chiesi plans Milan factory, Bharat Biotech builds CGT site, Aspen faces FDA warning, Currax adds Contrave site, Redwire aids ...

Nkarta cuts 53 jobs, Felix Baker joins Bicycle board, Kelso gets £140M, Arbutus cuts 19 jobs, Ascletis shifts to obesity, ...

Equillium's itolizumab fails Phase 3 trial for acute graft-versus-host disease, but company plans FDA accelerated approval ...